Skip to main content
. 2021 Nov;32(11):2900–2911. doi: 10.1681/ASN.2021030391

Figure 1.

Figure 1.

Association between changes in UACR during the 6-weeks response-enrichment period and subsequent kidney outcomes recorded during the double-blind treatment period. (A) The association in participants who continued atrasentan during the double-blind treatment period. (B) The association in participants who transitioned from atrasentan to placebo at randomization.